RESUMO
A new slow-release potassium phosphate preparation (Urophos-K), designed to minimize gastrointestinal side effects and avoid sodium-induced calciuria was tested in stone-formers with absorptive hypercalciuria(AH). In a prospective, randomized, double-blind tria1, 17 patients with AH received either Urophos-K (155mg P, 8 mEq K per tablet) 4 tablets twice daily or an identical placebo. Subjects were studied during a 4-day period in the hospital while consuming a constant metabolic diet containing 400mg Ca, 100meq Na, 800mg P/day before and after 3 months of treatment. The parameter of agglomeration inhibition ([h]) increased from 78.3+/-28.1 to 133.3+/-46.2 min4, consistent with the inhibitory action of citrate and pyrophosphate. Treatment with Urophos- K reduces urinary stone-forming potential.